IL17A and psoriatic arthritis: The monoclonal antibody secukinumab is specifically designed to selectively target and suppress the pro-inflammatory cytokine IL-17A, which play a pivotal role in autoimmune diseases, such as psoriasis, ankylosing spondylitis, and psoriatic arthritis (57).